Screening for thrombophilic mutations such as MTHFR C677T, factor V Leiden, and prothrombinG20210A in RVO patients at all ages seems to be unnecessary and not cost-effective.
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion.
We performed a meta-analysis on the associations between RVO and PAI-1 (n = 5), factor V Leiden (n = 21), MTHFR C677T (n = 19) and prothrombinG20210A (n = 21).
The aim of this study was to establish whether the factor V Leiden mutation and the prothrombin 20210 G:A mutation were risk factors for retinal vein occlusion.